The CDC just issued a major alert about mpox—what does it mean for you? This new warning has many asking questions about their health.

Stay tuned as we break down what you need to know and how to stay safe.

Understanding the recent mpox alert​

The CDC's recent communication to healthcare providers across the United States serves as a crucial reminder to be vigilant for symptoms of mpox, particularly in individuals who have traveled from regions where the virus is more prevalent.

This alert follows the report of a more severe case of mpox in California, identified in a traveler from Africa.

While this might sound alarming, it's important to note that no additional cases of the severe strain have been reported, and the CDC reassures that the risk to the general public remains low.

What is mpox?​

Mpox is an infectious disease caused by the mpox virus, which belongs to the same family of viruses as smallpox.

There are two main clades, or genetic branches, of the virus: clade I and clade II.

Clade I is typically associated with more severe illness and has been endemic in parts of central and western Africa.

The symptoms of mpox include a distinctive rash, often accompanied by fever, headache, muscle aches, and swollen lymph nodes.

The rise of mpox cases​

Globally, there has been a significant increase in mpox cases, particularly in the Democratic Republic of Congo, where thousands of cases and numerous deaths have been reported this year.

In contrast, the United States has seen a decrease in cases from the 2022 outbreak, with 2,368 cases of the less severe strain reported as of November 1, according to CDC data.

Who is at risk?​

The risk of contracting mpox remains low for the average American.

However, individuals who have recently traveled to areas where the virus is more common, or those engaging in high-risk activities with travelers from these regions, should be more cautious.

The incubation period for mpox can range from three to 18 days, so monitoring for symptoms after travel is essential.

Prevention and vaccination​

One of the most effective ways to prevent mpox is through vaccination.

The JYNNEOS vaccine, a two-dose regimen approved by the Food and Drug Administration (FDA), has been shown to be at least 85% effective in preventing mpox infection.

While there is no current recommendation for a booster for those at high risk who are already fully vaccinated, the FDA has authorized a strategy to increase vaccine availability by administering it intradermally, allowing more doses to be distributed from a single vial.

The CDC's alert is a proactive measure to ensure that healthcare providers and the public remain aware of mpox and its potential spread.

For those in at-risk groups, vaccination is recommended. For the general population, staying informed and alert is key.

Recognizing symptoms and seeking medical advice if you suspect exposure to mpox can help prevent further transmission.
Have you or someone you know been affected by mpox? Share your experiences with us in the comments below.